Multiple Myeloma · line 3 · Teclistamab BCMA × CD3 bispecific (with step-up dosing) — continuous SC weekly
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Line of therapy | 3 |
|---|---|
| Track | aggressive |
| Linked regimen | REG-TECLISTAMAB |
| ID | IND-MM-RR-3L-TECLISTAMAB |
|---|---|
| Type | Indication |
| Status | reviewed 2026-04-29 | pending_clinical_signoff |
| Diseases | DIS-MM |
| Sources | SRC-ESMO-MM-2023 SRC-MAJESTEC-1-MOREAU-2022 SRC-NCCN-MM-2025 |
Notes
STUB — requires two clinical co-lead signoffs before publication (CHARTER §6.1). Sibling to existing IND-MM-4L-TECLISTAMAB (4L framing); this entity uses RR-3L framing per Tier-2 manifest (tier2-ind-mm-2026-05-01-021). MajesTEC-1 source available; NCCN-MM-2025 + ESMO-MM-2023 supplementary citations satisfy Q4 ≥2-source axis.
Used By
No reverse references found in the YAML corpus.